Fig. 3
Expression levels of CYP1B1, KMO, and TDO2 and their relationships with the prognosis of ccRCC patients. a-c Representative IHC staining of CYP1B1, KMO, and TDO2 in tumor tissues and adjacent normal tissues; scale bar, 200 µm. d-f The expression of CYP1B1, KMO, and TDO2 in tumor tissues and adjacent normal tissues. g-i Kaplan–Meier survival analysis of the prognosis of patients with ccRCC with low or high expression of CYP1B1, KMO, and TDO2. j-l The expression of CYP1B1, KMO, and TDO2 in the ccRCC cell line (ACHN) and the control cell line (HK2)